Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Omeros Fell Over 13% Today

By Maxx Chatsko – Aug 12, 2020 at 12:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biopharma announced the pricing of a public offering of common stock and debt offering.

What happened

Shares of Omeros (OMER 3.94%) fell as much as 13.3% today after the company announced the pricing of a public offering of common stock and more details about a debt offering. 

The biopharma will offer up to 7.9 million shares of common stock at $14.50 apiece, which would haul in gross proceeds of roughly $115 million. Investors are displeased that the offering price is far below the $20-plus mark shares soared to after the company reported encouraging results from a six-patient study in COVID-19-associated acute respiratory distress syndrome (ARDS).

In addition to the stock offering, Omeros Corporation is issuing up to $241.5 million in convertible debt that bears 5.25% interest and comes due in 2026. As of 11:51 a.m. EDT, the small-cap stock had settled to a 12.4% loss.

A scientist looking through a microscope.

Image source: Getty Images.

So what

Investors cannot fault Omeros for taking advantage of favorable news recently, especially considering the business ended June with just $16 million in cash. But these transactions are relatively enormous for a company with no track record of commercial success. The biopharma has only been valued above $1 billion for a handful of days in the last five years.

Recent results from a six-patient study in COVID-19-associated ARDS were encouraging. All patients required mechanical ventilation, but were removed from ventilators, survived, and were discharged from the hospital after receiving the company's monoclonal antibody narsoplimab.

However, the study was not a clinical trial (it was a compassionate-use study) and involved just six individuals. Although Omeros Corporation announced it was in discussions with U.S. government agencies to broaden the use of the drug candidate, the U.S. Food and Drug Administration (FDA) will almost certainly require the company to conduct a larger, placebo-controlled clinical trial first. Investors who doubt that should consider Capricor Therapeutics and Mesoblast each had similarly promising results in small compassionate-use studies, but are now conducting controlled clinical trials with hundreds of individuals in an attempt to replicate the results. 

Now what

If the stock and debt offerings proceed without a hitch, then Omeros Corporation will be loaded with cash to plow into a larger clinical trial for narsoplimab in COVID-19-associated ARDS, among other things. But designing and completing such a study will take months -- and it isn't guaranteed to replicate the results of the smaller study. For now, investors should take a wait-and-see approach. 

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Omeros Stock Quote
$3.96 (3.94%) $0.15
Mesoblast Limited Stock Quote
Mesoblast Limited
$2.99 (0.34%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.